Novel Therapy Shows Promise in Treatment of Triple-Negative Breast Cancer Cells

Novel Therapy Shows Promise in Treatment of Triple-Negative Breast Cancer Cells
In recent years laboratory studies using AMPI-109 — a novel alkylating analog of vitamin D — have shown the experimental therapy is a potential killer of triple-negative breast cancer cells. But no matter how positive the results in the lab, anti-tumor drugs can only be included in a human clinical trial when researchers know their mechanisms of action.

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *